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In this paper, we summarize published articles and experiences related to the attempt
to improve radiotherapy outcomes and, thus, to personalize the radiation treatment
according to the individual characteristics of each patient. The evolution of ideas and
the study of successively published data have led us to envisage new biophysical
models for the interpretation of tumor and healthy normal tissue response to radiation.
In the development of the model, we have shown that when mesenchymal stem cells
(MSCs) and radiotherapy are administered simultaneously in experimental radiotherapy
on xenotumors implanted in a murine model, the results of the treatment show the
existence of a synergic mechanism that is able to enhance the local and systemic
actions of the radiation both on the treated tumor and on its possible metastasis. We are
convinced that, due to the physical hallmarks that characterize the neoplastic tissues, the
physical–chemical tropism of MSCs, and the widespread functions of macromolecules,
proteins, and exosomes released from activated MSCs, the combination of radiotherapy
plus MSCs used intratumorally has the effect of counteracting the pro-tumorigenic and
pro-metastatic signals that contribute to the growth, spread, and resistance of the tumor
cells. Therefore, we have concluded that MSCs are appropriate for therapeutic use in a
clinical trial for rectal cancer combined with radiotherapy, which we are going to start in
the near future.
Keywords: experimental radiotherapy, cell loss, mesenchymal cells, bystander effect, abscopal effect, exosomes,
mesenchymal cell enhancement ratio
INTRODUCTION
In clinical oncology, each patient is different. Therefore, the treatment should also be different;
that is, each patient needs a specific treatment adjusted to their characteristics and the prognosis of
the illness.
For most neoplastic diseases, the prognosis of the disease is a function of a small number of
variables. Although the choice of these variables is supported by a broad medical consensus and
it is assumed that each treatment is considered to be the most appropriate to achieve a cure, the
number of therapeutic failures that result constitutes a medical problem of singular importance.
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Currently the treatment of cancer patients is decided on
the basis of the size of the tumor, the status of the loco-
regional lymphatics, the presence or absence of distal disease,
the histological type, and the general health state of the
patient. Once the necessary values are known, the patients
are classified (the staging) into well-defined clinical categories
(1). This classification is so that the physician has a general
approach to the prognosis of the illness suffered by the
patient being treated, and that the treatment proposed is most
appropriate and above all offers the patient the necessary
information to decide and consent to how he/she wants to
be treated.
Ionizing radiation is widely and effectively applied in
oncology. However, due to dose limits, a complete tumor
cure cannot be achieved for many tumors and localizations.
Despite the advanced radiotherapy facilities and therapeutic
methods that are currently available, high doses of radiation
might still induce, fortunately only on rare occasions, early
and late side effects of severe magnitude. Unacceptable normal
tissue reactions persist as the limiting factor for administering
a tumoricidal dose in radiotherapy. Moreover, the frequent
presence of clinical and/or hide-metastatic foci in distal
organs is beyond the range of the treatment and is a death
threat for the patients. Therefore, research searching for
progress in the control of metastatic disease is a target of
major interest.
The previous paragraph reveals that both the study of the
extension of the neoplasms and the prediction of the probabilities
of tumor control or complications after therapy are based on
techniques that are imperfect, imprecise, and insufficient. Indeed,
when the results of therapy in groups of patients classified
to be at the same stage are studied in the long term, a
variability of response is found, which is impossible to predict
(1–6).
The evolution of ideas and the study of successively
published data have led us to imagine a new biophysical
model for the interpretation of tumor response to radiation.
In its development, we have shown that when human-
umbilical cord mesenchymal stem cells (MSCs) and
radiotherapy are administered simultaneously in experimental
radiotherapy on xenotumors implanted in a murine model,
the results of the treatment show the existence of a synergic
mechanism that is able to enhance the local and systemic
actions of the radiation both on the treated tumor and
on its possible metastasis. We are convinced that due to
the physical hallmarks that characterize the neoplastic
tissues, the physical–chemical tropism of MSCs, and the
widespread functions of macromolecules, proteins, and
exosomes released from activated MSCs, the combination of
radiotherapy plus MSCs used intratumorally has the effect of
counteracting the protumorigenic and pro-metastatic signals
that contribute to the growth, dissemination, and resistance of
the tumor cells.
Therefore, we have concluded that the administration of MSC
enhances the therapeutic effect of radiotherapy in vivo and does
not produce toxic effects, indicating that they could be used
as an adjuvant treatment for cancer, increasing the therapeutic
effect of radiotherapy on the tumor as well as on possible tumor-
metastatic foci.
The three objectives of this study are:
a. to propose a biophysics model that includes the classic
radiobiological concepts together with the bystander and
abscopal effects in a single picture.
b. to summarize results of our in vivo studies that demonstrate
of the synergist effect of radiotherapy combined with
mesenchymal cell therapy in the treatment of xenotumors.
c. to suggest that exosomes and proteins secreted by the
activated-mesenchymal cells are responsible for the
enhancement of radiotherapy action on the tumor, including
the abscopal effect on tumor-metastatic foci.
THE ROLE OF RADIOBIOLOGY
The cellular consequences of direct radiation-induced DNA
damage, producing lethal and potentially lethal damage to
DNA, can be described by radiation cell survival models (7).
Nevertheless, although we agree with Brown et al. (8), who
suggested that, for the most part, the universally accepted
radiobiology ideas of the 5 Rs (9) are enough to describe the
clinical data and the isoeffect or tolerance calculations, we are
convinced that the results obtained from the application of the
LQ model (10, 11) in clinical studies through the calculation
of biologically effective doses (BEDs) are absolutely correct,
and that this model has also been successfully used, even with
stereotactic radio-surgery (SRS), intraoperative radiotherapy
(IORT), and stereotactic body radiotherapy (SBRT), although
with the probable exception that, for some tumors in which high
doses of irradiation may produce greater anti-tumor immunity
(8), the role of the 5 Rs of radiotherapy is clearly different in these
cases (12).
However, considering that the LQ model can explain neither
the bystander effects (13–15), nor the variation of damage
processing and tissue remodeling in the pathogenesis and
severity of the of the late effects of radiation (16–18), nor
the abscopal effects that can be intermediated principally by
immune cells such as the T cells (19), it is clear that the
models so far used to interpret the relationship between cell
radiosensitivity and clinical radio-response are unable to explain
all the effects of radiation in some circumstances and a more
general radiobiological model appears to be mandatory (6, 20).
WE MUST UNDERSTAND THE WHOLE
RESPONSE OF TUMOR AND NORMAL
TISSUE TO RADIOTHERAPY
The happening of hyper-radiosensitivity at low radiotherapy
doses (13) and the bystander effect (14–16) exemplifies that
reactive molecular signaling and repair activity regulate the
equilibrium of irradiated potential lethally damaged cells between
radiation cell killing and cell survival, and this communication
between irradiated and out-of-target cells can affect tumor cells,
reducing their surviving fraction (17, 18).
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Mounting data suggest that radiotherapy also recruits
biological effectors away from the treatment field and has
systemic effects (19, 20).
Consequently, in our view, non-target radiotherapy action
could be thought as the complete immunological reaction of the
tumor (21–25) and health tissues (6, 26) to the stress caused
in the irradiated volume (27) that results in enhanced levels of
DNA lesions (21), chromosomal aberrations (28), alterations in
transcript levels and gene expression (29–32), and finally cell
death (18, 33). The major question, however, is how to combine
diverse information (clinical, imaging, and molecular data) in an
algorithm to offer specific clinical information that precisely and
significantly estimate patient outcomes as a function of potential
therapeutic decisions (34).
We consider that neoplastic stem cell survival after radiation
treatment be determined by (a) the effects of radiation-induced
cellular damage (linear-quadratic model) and (b) the out-of-
target bystander and abscopal interaction produced by free
radicals, antigen–antibody interaction (19), and death receptor–
ligand interaction (18, 35, 36).
The Biophysical Model
Assuming that the targeted action of radiation on the cell DNA
and the non-targeted (bystander or abscopal) actions on cell
survival are independent as has been proposed recently (37), our
previously published model (35, 38) defines the final surviving
fraction as the product of the surviving fraction produced by
the targeted interaction of radiation with the tumor cells and the
cell surviving fraction on tumors and metastatic foci through the
short-range and long-range bystander effects that are promoted
by the radiation treatment (18, 35).
Based on these concepts, we have described that, after
radiation, cells in the therapeutic volume can be classified into
four compartments (Figure 1) that we briefly update here:
Undamaged Cells (A)
Survival response of cells after each fraction of dose, which should
be controlled with consecutive irradiation treatments.
Dead Cells (B)
This is the lethal-lesion compartment in Curtis’s model (39) that
arise from the targeted and non-targeted action of radiation
on DNA, and from the bystander and abscopal immunological
cell death promoted by the action of activated cells (38, 40)
and death cells (35, 40–42) on other tumoral cells belonging to
tumor process.
Activated Cells (C)
Cells that are either slightly damaged or have been able to
restore their lesions to a level of residual damage compatible with
survival. These cells might turn out to be an effective source of
cytokines (38), macromolecules (43), exosomes (44, 45), reactive
oxygen species (46), and reactive nitrogen species (18), and/or
could suffer phenotypic changes to express hide-antigens in the
tumors, which allow the triggering of the pro-immunogenic
effects of radiotherapy on the tumors (19, 20, 47), with none of
these possibilities being exclusive of the others, indeed all of them
FIGURE 1 | Schematic representation of the biophysical model for direct,
bystander, and abscopal actions of the radiotherapy and the enhancement
produced by the addition of cellular therapy through mesenchymal cell
transplantation simultaneously applied with radiation therapy. Rt-I-CD,
radiation-induced cell death on tumor cells; By-I-CD, short and long-range
bystander-induced cell death on tumor cells; Abs-I-CD, abscopal-induced cell
death on metastatic foci. The three types of induced cell death are enhanced
by the combination of radiotherapy and cellular therapy, and the compartment
of activated cells responsible for bystander and abscopal effects, labeled with
(C) in the figure, may be enlarged by mesenchymal cell transplantation.
might affect the local and distal burden of tumor cells (48) and
be the cause of the bystander and abscopal components of the
radiation immunologically induced cell death on local and distal
foci of the tumors (35).
As we will explain below, this compartment may be enlarged
by human-umbilical cord MSC transplantation (38, 44, 49).
Committed Cells (D)
This compartment corresponds with the potentially lethal lesions
in the LQ Equation (7, 39); cells in this compartment can flow
back to compartments (A) or (B) through proper repair or
binary misrepair.
Operational Terms
As operational purpose, we considered:
Short-Range Bystander Effect
It is generally accepted that the use of ionizing radiation
to a treatment volume that contains the tumor causes
effects that go beyond radiation-induced cell death (14),
revealing intracellular transmission that implies the gap-
junction intercellular connection and ends in cell death,
enhanced amounts of DNA double-strand breaks, induction of
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chromosomal aberrations, and/or alterations in transcript RNA
levels and gene expression (50).
Long-Range Bystander Effects
Results obtained from “in vivo” irradiated tumors suggest
that tumors may exert their influence far beyond its own
microenvironment to spread peritumoral region and tissues far
away from a tumor. The long-range bystander effect is generated
by cytokines, macromolecules, and exosomes liberated into the
extracellular space (38, 40, 44) that, through the lymphatic
or vascular systems, might substantially alter conventional
expectation in radiotherapy by yielding loco-regional positive
effects (35).
Abscopal Effect
The abscopal effect is an anti-tumor radiation consequence seen
in metastatic disease placed far away from the irradiated tissue.
High-dose ablative radiotherapy results in release of debris of
tumor cells containing molecules that may be immunogenic (51).
Therefore, radiotherapy could imitate the effect of vaccination,
as an unconventional method to present tumor antigens making
cancer cells more receptive to T cell-mediated cytotoxicity (52).
This effect could be associated first with the larger than usual
effect of single doses by standard models (53), thus facilitating
excellent local control rates, second to the unexpected abscopal
effect. In this sense, new original associations of RT with
immunotherapies have been designed to reverse tumor immune-
related radioresistance (54), and the reactivation of the anti-
tumor immune response can be considered as the 6th R of clinical
radiobiology (36), opening an exciting field in patient treatment.
It is important to underline that unlike an increased reply
concomitant with an escalation in radiation dose, the bystander
reaction reaches a saturation level at comparatively low doses
(18, 50).
The Mathematical Model
A key feature of bystander responses, as opposed to direct
irradiation effects, is the dose–response relationship. Instead of
a continuously increased response related with an increase in
dose, the bystander response turns out to be saturated at low
doses. This might indicate a receptor–ligand interaction, which
we took as our original hypothesis (18), with the characteristic
of being simultaneously dynamic and reversible. The same
kinetic mechanism could be used to describe the antigen–
antibody interaction.
Assuming the radiation and bystander consequences on
tumor cell survival to be independent (38, 44), the whole response
of the tumors and their metastatic foci to radiation therapy might
be expressed as the product of the probability of radiation tumor
cell death times the probability of cell death through bystander or
abscopal effects (18, 37).
Data now indicate that, as well as these targeted DNA damage
dependent effects, tumor cells and normal tissue-irradiated cells
(activated cells) and immunological cell death also transmit
signals to their adjacent cells (35). Here, we think that clonogenic
cell survival S after radiation therapy depends together with the
direct effects on DNA through radiation interaction SRT and
bystander and abscopal communication 5 SBy. Thinking that
DNA damage caused by radiation and short- and long-ranged
bystander effects on tumor cell survival are independent, the
whole tumor response may be said as:
S = SRT ·
n∏
i = 1
SBy(i) (1)
where the first term of the product of cell survival calculated
using linear-quadratic model represents the pure RT action on
the irradiated tumor and the second term, which begins with
the 5 symbol, is the product from n = 1 to n = n of the cell
death probabilities resulting from each one (i = 1. . . i = n) of the
out-of-target cell death actions (bystander and abscopal effects)
promoted for the combined treatment (RT + MSCs) that was
used in our last papers. A set of these possibilities has been
summarized here in the point section Activated Cells (C).
Following the same reasoning that we indicated in our
previous paper (35), this entails that the chance of cell survival
depends on both the direct radiation effect (the LQ model) and
bystander effects, with these effects also being a phenomenon
composed of long- and short-range bystander actions, whose
importance, at least in experimental RT, may be estimated.
The final values of tumor cell survival (S) suggest that the
lethal effects of radiation on tumor cells can be significantly
enhanced by unanticipated interactions between live cells with
the secretome of activated cells (14, 44) or with the molecules
released after immunological cell death (42).
This model helps us to comprehend how anticancer treatment
may have an additional and significant effect in that the radiation-
activated MSC∗ cell response could be important for therapy
to be successful due to the fact that the survival of tumor cells
interconnecting with irradiated and activated cells is reduced.
THE LONG-RANGE BYSTANDER EFFECTS
AND THE ABSCOPAL EFFECT OF
RADIOTHERAPY
Anti-tumor consequences beyond the radiation field have been
identified (43, 47, 55–61) and the regression of remote metastasis
after tumor radiotherapy has been recently described in human
melanoma skin cancer (48, 62, 63) and other tumor locations
(64, 65).
Over recent years, the abscopal mechanism has been clarified
by the effort of several investigators, including Formenti and
Demaria (19, 20), who revealed that this activity was probably
facilitated by the immune system leading to immunogenic cell
death, a mechanism that implicates dendritic cells, T regulatory
cells, and suppressor cells as key intermediaries. Radiation
therapy sensitizes unresponsive tumors to the anti-neoplastic
action of antibodies that target the inhibitory receptor CTLA-
4 on T cells (66). Multiple studies have demonstrated that
radiotherapy can increase the efficacy of anti-PD1 therapy by
priming and recruiting more anti-tumor effector T cells (67, 68)
and recently it has been suggested that the addition of immune
checkpoint inhibition with local radiotherapy might increase
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local and distant metastatic control and, in the end, the clinical
results of disease control in patients with oligometastatic cancer
(69). Moreover, the idea to generate an integrated clinical and
molecular categorization of metastases along the spectrum of
disease is very interesting, because this approach may perhaps
influence the staging and treatment of patients with cancer
diseases (70).
Golden and colleagues (42) were the first to prove that
abscopal responses can be consistently identified in patients
with confirmed solid metastatic cancer treated with radio-
and immune-therapy. The combined treatment with and the
granulocyte-macrophage colony-stimulating factor generated
clear abscopal responses in certain patients with metastatic
diseases, and this finding signifies a hopeful advance to
establishing an in situ anti-tumor vaccine (71). Recently
published results prove that radiotherapy in combination with
the CTLA-4 blockade (72) or the PD1 blockade (68) produces
systemic effects in patients with cancer. The early response in
the TCR clonal dynamic detected in responders is coherent with
a change and increase of the tumor-directed TCR repertoire
provoked by radiation therapy and its study in representative
cases means that increase of a huge amount of tumor-specific
T cell clones in peripheral blood and their presence over time
correlated well with the occurrence of abscopal outcomes (72).
In spite of the growing number of clinical studies examining the
ability of radiation to improve immunotherapy, clinical proof
that it transforms cold tumors with little to no immune response
into responsive ones remains elusive (66).
Nevertheless, it seems clear that reasonable combinations
of immunotherapy with RT may dramatically change the
model of care for many tumor types in the following
decade (73).
MESENCHYMAL CELLS AS BIOLOGICAL
RESPONSE MODIFIERS
It is generally recognized that MSCs can be found commonly in
numerous tissues and are not limited to those of mesodermal
origin, such as bone marrow, adipose, muscle, and bone (74).
On the other hand, it has recently been revealed that in vitro
differentiation of human MSCs is linked by an augmented
sensitivity to apoptosis, which is in significant divergence
to undifferentiated MSCs, which are moderately resistant to
irradiation or temozolomide-induced DNA damage (75). We
have demonstrated that MSCs are relatively sensitive to low-LET
irradiation and very resistant to the bystander effect produced by
the culture medium of irradiated cells (18).
Stem cell knowledge has also become the basic element in
regenerative medicine (76, 77).
It is an exciting idea that inhibiting the mechanism that
facilitates the bystander effect can give rise to therapeutic
approaches that stimulate the radio-sensitivity of cells or protect
healthy tissue against the damaging effects of ionizing radiation
(78). Previous reports suggested a protective role for MSCs when
combined with RT (79, 80). In effect, study on mesenchymal
stem cell therapy for wounded and unhealthy tissues, involving
the intestines, has been highly encouraging. Therapy with bone-
marrow-derived or vascular-wall-derivedMSCs protects the lung
tissue from radiation-induced vascular damage and antagonizes
the metastatic potential of circulating tumor cells to formerly
irradiated lungs (81).
The use of human grade MSC is challenging and must
fulfill EMA or FDA requirements to regulate autologous adult
stem cells for therapeutic application. This has been widely
summarized and discussed (82, 83) and we know that MSCs,
commonly mentioned to as MSCs or mesenchymal stromal
cells, are a varied population of cells that must be properly
characterized. To clarify this controversial aspect, different
papers have been published in the latest years (84–86) and
contribute to the understanding of the composition of MSC-
based products and provide the way to assess their in vitro and
in vivo bioactivity.
Due to their properties, MSCs might be suitable as a
therapeutic tool for handling radiation-induced normal
tissue injury (84, 87). Numerous papers have demonstrated
that administered either intraperitoneally or intravenously,
MSCs effectively home onto primary tumors and their
metastases (85, 86). Moreover, before supporting tissue
repair functions, MSCs first organize the microenvironment
by controlling inflammatory processes and releasing a variety
of growth factors in reaction to the inflammation process
(88). Due to their trophic, paracrine, and immunomodulatory
functions, they may have the highest beneficial impact in
vivo (89). However, the amount of MSCs that engraft into
damaged tissues might not be enough to explain their robust
protective effect.
The therapeutic efficacy of transplanted MSCs seems to be
unconnected to the physical proximity of the transplanted cells
to damaged tissue. Thus, we believe that the predominant
mechanism by which MSCs contribute in tissue repair might
be related to their paracrine activity, and in this way, it is also
possible to think of the additional use of MSCs as an adjuvant
to support and complement other therapeutic options as has
recently been recently proposed (65, 90).
IS IT POSSIBLE TO WIDEN THE
BYSTANDER AND ABSCOPAL
RADIOTHERAPY EFFECTS?
MSCs have been studied for the treatment of cancers as they are
able to home onto tumors and come to be incorporated into their
stroma. Moreover, MSC homing is enhanced after radiotherapy
(45). MSCs can both suppress or stimulate tumor progression
(91–93). It has been described that the bioactivation ofMSCsmay
be achieved by different treatments and the molecules secreted by
the activated MSCs (MSCs∗) could have an influence on a variety
of immune cell lineages and establish a beneficial field (40).
We have recently shown that optimal bystander and abscopal
effects can be obtained using MSCs plus RT administered on an
experimental murine model with two xenotumors symmetrically
placed in the upper region of both the rear legs, with only one of
them being treated with radiotherapy (38, 44).
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In a recently published article, the influence of MSC
cell therapy on the progress of solid tumors using an
orthotopic cancer model of human colorectal cancer cells
has been studied, as well as in an immunocompetent rat
model of colorectal carcinogenesis representative of human
pathology (49). In their results, the authors show that MSC
administration to immunocompetent rats treated topically with
methylnitronitrosoguanidine (MNNG), a strong carcinogen,
reduced the growth of the tumors and improved overall
survival. In this experimental cancer model, the MSCs
have strong action on colon cancer growth by altering the
immune component of the tumor microenvironment. In
an important concordance with our research (38, 44), when
MSCs were administered after therapy of colorectal cancer
(CRC) with fractionated irradiation, MSCs reduced tumor
growth, extended animal survival, and reduced the presence of
metastatic foci.
The MSCs also protected healthy tissue from radiation
damage by rising the levels of growth factors, reducing fibrosis,
and facilitating intestinal recovery (49).
Taking into account both the previous reports and
our own experience and research on the extraordinary
abilities of proliferation (94, 95), secretion (44, 96), and
differentiation (95) of the umbilical cord mesenchymal cells
that we have investigated (38, 44) and used in combination
with radiotherapy in recent years, we have developed the
following hypothesis:
“Radiotherapy may not only be a successful local and regional
treatment but also a novel systemic cancer therapy” (38).
To check this hypothesis, we used a set of human cancer cell
lines implanted in NSG mice as xenotumors and MSCs obtained
from human umbilical cord stroma. We have investigated the
tumor response to direct irradiation (2Gy low-LET radiation
fraction administered once a week for 5–6 weeks) and, in the
non-irradiated contralateral tumor, the tumor sensitivity to the
bystander effect.
In our experiments, mice with tumors larger than 60 mm3
were treated with an intraperitoneal administration of 106 MSC
once a week for 5–6 successive weeks (38, 44). The day after
each cellular therapy, one of the four groups of mice was
randomly chosen to have one of their tumors irradiated. Ionizing
radiation was delivered by X-ray TUBE (YXLON, model Y,
Tu 320-D03) as explained previously (38, 44). The treatment
was repeated once a week for a total of 5–6 weeks. The other
mice groups were treated with exclusively RT or exclusively
MSC. The mice in the control group received no treatment
(38, 44).
We have proved that tumor cell loss induced after treatment
with radiotherapy enhances with the therapeutic combination of
RT and MSCs, when compared to RT alone, in the three cell
lines (A375, G361, and MCF7) used, and also that, through the
bystander and abscopal effect, the therapeutic combination (RT
+ MSC) had a positive effect on the tumor-volume reduction
of the contralateral, untreated tumor (Table 1). When the cell
line used had metastatic potential, the combination (RT+MSC)
produced a reduction in the microscopic number of metastasis in
the internal organs of mice with A375 xenotumors (44). These
results prove conclusively that the combination of MSC + RT
produces a synergic, bystander, and abscopal effect.
In Table 1, notice the differences in the tumor volume
doubling time values (TD) corresponding to different cell lines
treated with RT (from 7.60 to 17.60 days) and observe, also, the
differences between the control and MSC+RT groups for each
of the tumor cell lines implanted as xenotumors (from 22.5 to
38.9 days) and the gains derived from the addition of MSC to the
RT treatment, measured as the mesenchymal cell enhancement
ratio (MSC-ER), ranged between 1.60 and 2.00 and more than
3.00 for A375 in our last paper (44) designed to evaluate the anti-
metastatic potential of MSCs combined with RT, when the tumor
volume was followed only in the first 14 days.
It is important to analyze that the time-to-tumor growth to
a volume of 2ml reached an increase in time ranging between
12% for A375, the most aggressive cell line, and 117% for MCF7,
the least aggressive. For details on the mathematical model used
[see (38, 44)]. It is important to highlight that G361 and A375 are
human melanoma cell lines, whereas MCF7 is a cell derived from
a human breast cancer.
We define cell loss factor as CL = 100·[1 –
TD(control)/TD(treatment)]; in which TD(treatment) is the
volume doubling time in each of the treatment groups: MSC
+RT and RT.
MSC-ER: the mesenchymal enhancement ratio is the ratio
between the cell loss corresponding to the combined treatment
divided by the cell loss corresponding to the treatment with
radiotherapy alone.
CL: in the cell-loss factor, the following are included: (i) all
the types of cell death, (ii) lengthening of the mean cell cycle
duration produced by the treatment, and (iii) cells that have a
null or limited growth potential due to misrepair of damage or
because they have been involved in a differentiation process.
The abscopal effect has been estimated by the reduction of
metastasis index that was 60% in the A375 cell line, with the
difference between the control and RT + MSC groups being
statistically significant (P = 0.002). In our experiments, A375 is
the only cell line that has showed metastatic potential. It is very
important to note that the amount of metastatic foci observed in
the internal organs of the mice treated with MSC + RT was 60%
fewer than in the mice treated with RT alone (44).
Moreover, in our last paper (44) (supplementary materials),
we demonstrated that MSC, previously activated with 2Gy low-
LET radiation dose (MSC∗) and used after tumor radiotherapy
as adjuvant cellular therapy, retained a wide cytotoxic activity
that affected the volume of the xenotumors treated, thus
enhancing the therapeutic effect of radiotherapy in a similar
level to that we have communicated previously (38, 44).
Using these MSC∗-activated cells, we found that when the
tumors implanted in mice were first treated with radiotherapy
and then treated immediately after the end of RT with
infused intraperitonially MSC∗ activated, the tumors treated
in this way significantly reduced their tumor growth rate
compared with both control mice and mice treated with
radiotherapy alone.
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TABLE 1 | Characteristic growth kinetics parameters of the treatment of xenografts implanted in NSG mice on control and MSC + RT groups.
Parameter Tumor cell line
G361 A375 MCF7
RT MSC + RT RT MSC + RT Control MSC + RT
TD (days) 11.5
(CI: 10.6–12.6)
22.5
(CI: 18.7–28.1)
7.6
(CI: 5.3–5.7)
8.5
(CI: 8.1–8.9)
17.6
(CI: 17.2–18.2)
38.9
(CI: 32.3–47.5)
CL (% days−1) 47.0 72.3 9.6 18.8 – 55.9
MSC-ER 1.6 2.0 Not calculated
T-t-G (days) 60.8 91.1 32.8 36.6 195.0 422.3
Mx No Yes: 1.0±0.4 Yes: 0.4±0.1 No
% reduction Mx index: 60%; P = 0.002
TD, tumor volume doubling time (days); CL, cell loss factor in a treated tumor compared to a control tumor (%·days
−1); MSC-ER, radiotherapy mesenchymal cell enhancement ratio
= (cell loss produced by the combination RT + MSC)/(cell loss produced by RT alone); T-t-G, time-to-tumor growth (days) to reach a volume of 2.0ml; Mx, Metastasis index: % of
decrease in the histological identification of microscopic metastasis in the MSC + RT group, compared to the control group; CI, confidence interval.
Accordingly, the results obtained in our study regarding the
tumor doubling time (TD) values were different among the
groups, being longer for mice treated with RT + MSC∗ (8.46
days), compared with the control and RT groups (6.87 and 7.60
days, respectively).
Mesenchymal enhancement ratio (MSC-ER) is the ratio of
tumor effect produced by the combination of radiotherapy
plus MSCs therapy (RT + MSC∗) divided by the tumor effect
produced by exclusive radiotherapy. By means of doubling
the time values, we have calculated the MSC∗-ER values as
the proportion of cell loss CL (38) produced by RT +
MSC∗ treatment, compared to the cell loss CL produced by
radiotherapy treatment alone and demonstrated that activated
MSC∗ potentiated the radiotherapy effect when infused into
tumor-bearing mice with a MSC∗-ER of:
MSC∗ − ER =
CL (RT+MSC
∗ treatment)
CL (RT treatment)
=
18. 8%
9.6%
= 1.95
(2)
This result fits with previous results summarized in Table 1
and proves that the combination (RT + MSC∗) improves
the therapeutic efficiency respect to RT alone (both in tumor
and metastatic control) through enhancing short- and long-
range bystander and abscopal effects. For more details on
the mathematical model applied [see supplementary materials
in (37)].
CELLULAR THERAPY WITH MSCS: A
PROBLEM FOR ANTI-TUMOR THERAPY?
MSCs exist in many tissues and are recognized to actively be
recruited to primary tumors and metastasis and also to other
locations of normal tissue damaged, where they take part in
wound repair. Tumors can be thought of as “wounds that never
heal” and, in reply to signals from the neoplastic tissue, the
MSCs can exhibit a marked tropism that might contribute to
tumor growth promotion by several mechanisms that have been
reviewed recently (97).
Tumors continuously recruit cells from the tumor
microenvironment and become important elements of the
tumor volume, interchanging proper signals that might
acquire aggressive phenotypes of carcinoma cells and establish
a complicated situation that concludes in metastasis (98).
Recently, it has become apparent that tumor-associated MSCs
have an effective role in tumor induction, promotion, growth,
and metastasis (99), and although the tumor microenvironment
is constituted of numerous cell types including tumor, stromal,
endothelial, and immune cell populations, it appears clear
that, under the influence of these cells, MSCs acquire different
functional phenotypes that promote tumorigenesis (100),
permitting the tumor to avoid immune clearance or impeding
effectiveness through the acquisition of a chemotherapy and
radiotherapy resistance mechanisms (101). On the other hand, it
has been described that, in an inflammatory situation, resident
tumor MSCs strikingly enhanced tumor growth by engaging
monocytes/macrophages in comparison to bone marrow MSCs
(102, 103) and exosomes present in the cancer cell secretome
might be the principal agent able to modify the normal MSC cell
phenotype toward a malignant one (104).
Nevertheless, it is still controversial whether this innate
tropism of MSCs toward the tumors and metastatic foci
is linked with cancer promotion or suppression (105), and
it has been suggested that a better understanding of the
interactions between cancerous cells and stromal components
of tumor microenvironment is important to allow progress in
the development of more specific and useful therapies in cancer
(99, 100, 106).
EXOSOMES SECRETED FROM MSCS
HAVE A TOTALLY DIFFERENT EFFECT
FROM THE EXOSOMES RELEASED FROM
TUMOR CELLS
Cancer cell-derived exosomes have been shown to participate
in the key steps of the metastatic widening of a primary
tumor, ranging from oncogenic reprogramming of malignant
cells to the formation of pre-metastatic niches (107) and this
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mechanism may be facilitated by RT under certain conditions
(108, 109) or facilitated by released mir-939 in exosomes that,
once internalized in endothelial cells, play a protumorigenic role
for metastatic spread in association with triple-negative breast
cancers (110).
By studying the exosomes andmicrovesicles released by tumor
cells into the extracellular medium, we have been able understand
that exosomes from tumor cells spread through the biological
fluids and support tumor growth and metastasis formation (111,
112). There are several examples that confirm this hypothesis;
for example, it is well-known that the process of cancer cell
migration into the normal tissues and invasion-promoting effects
may be due to cancer-cell-derived exosomes (113, 114). After
release, the exosomes are taken up by neighboring or remote
cells facilitating tumor progression and the miRNAs confined
within the exosomes modify such processes as interfering with
tumor immunity and the microenvironment, suggesting that
exosomal miRNAs have a noteworthy role in regulating cancer
progression (115).
Pancreatic ductal adenocarcinoma (PDAC) is an exceptionally
aggressive tumor, characterized by a high metastatic potential,
even at the point of diagnosis; in a recent paper (116),
using proteomic studies, it has been shown that it is
possible to identify the impact of exosomes on the Kuppfer
cells in the liver, which may function to organize this
organ for metastatic occupation. Recently, the exosome-
mediated transfer of pyruvate kinase M2 (PKM2) from
PCa cells into bone marrow stromal cells (BMSCs) has
been identified as a new process through which primary
tumor-derived exosomes stimulate premetastatic niche
development (117).
Other published results (118) suggest that exosome-mediated
discharge of tumor-suppressor miRNA is selected in tumor
evolution as a mechanism to organize the activation of a
metastatic cascade (119). The load of exosomes is given for the
parental cells and the circumstances in which they deliver them,
which implies that circulating miRNAs in exosomes have the
ability to serve as prognostic and predictive biomarkers (120).
However, exosomes derived from MSCs play a completely
different role, and previous reports have suggested a protective
role for MSCs when combined with RT. Indeed, therapy
with bone-marrow-derivedMSCs or vascular-wall-derivedMSCs
protects the lung tissue from radiation-induced vascular
dysfunction and antagonizes increased metastases of circulating
tumor cells to previously irradiated lungs (81).
Exosomes produced by MSCs have been demonstrated
to contain antiapoptotic miRNAs to improve epithelial and
endothelial wound healing and angiogenesis, and to include
growth factor receptor mRNAs, well-known to facilitate wound
recovery and safeguard the intestines from experimental
necrotizing enterocolitis (121). Results of the research on
mesenchymal stem cell therapy for wounded and unhealthy
tissues, including the intestines, have been highly promising
(79, 80) and MSCs may be considered as a therapeutic tool to
deal with radiation-induced tissue damage (87).
It is important to underline that the group of Chapel et al.
(122) has initiated a phase 2 clinical trial (ClinicalTrials.gov
Identifier: NCT02814864) for the treatment of severe adverse
effects for patients receiving radiotherapy for prostate cancer and
that this clinical trail is supported by numerous papers focused on
the use of MSCs for alleviating the side effects on normal tissues
after radiation therapy (123–125).
However, the biodistribution and the mechanism involved in
the control of colateral side effects are not well-known, although
there are also some reports directed to investigating this problem
in more depth. But we do know that in an undamaged mouse,
exogenous intravenously injected MSCs quickly accumulate
within the lungs and are cleared from this site to other tissues,
such as the liver, within days (126). Nevertheless, the quantity
of MSCs that are uptaked for the injured tissues may not be
sufficient to explain their strong protective effects.
Moreover, in a cancer rat model used to study the treatment of
chemical-induced colorectal cancer (CRC) previously cited (49),
it has been demonstrated that exogenous MSCs, although only
briefly found in the colon tissue of treated animals, were able
to alter the immune profile of the tissue microenvironment as
far as 1 year after the last MSC administration, possibly due to
polarization of resident MSCs and immune cells.
To sum up, it is generally accepted that MSC-derived
microvesicles and exosomes have been proposed as a novel
mechanism of cell-to-cell communication that permits the
transmission of functional proteins or genetic material via
mRNAs andmicroRNAs upon cell activation that may encourage
a new approach for repairing acutely damaged organs by virtue of
the exclusive MSC tropism for the injured tissue, as well as their
paracrine action in nature and facilitated through the decrease of
inflammation and enhancement of tissue repair (127).
On the other hand, our in vitro and in vivo results show that
TRAIL and DKK3 are molecules delivered by mesenchymal cells
that, as consequence of the cell treatment with 2Gy low-LET
gamma radiation, are released to the extracellular space where
they can work as signaling molecules to yield tumor cell death
(38, 44). The ability of MSCs to release TRAIL to culture medium
that inhibits the growth of human cancer cells has recently been
confirmed (128). Exosomes and microvesicles also appear in
the extracellular medium of cell cultures that are quantitatively,
qualitatively, and functionally different if they are removed from
the MSC medium or from the activated MSC medium (44).
Together, all these results indicate that the administration of
MSCs might be a safe and innovative therapeutic alternative to
heal normal tissue after cancer radiotherapy (49).
ANNEXIN A1 AS A CANDIDATE FOR
ENHANCING RADIOTHERAPY
When we examined the exosome load before and after the
activation of MSCs with RT, we noticed statistically significant
differences between the results of the proteomic analysis
corresponding to the samples.
We have described that there are qualitative, quantitative,
and functional variations among the proteins included in the
exosomes found from MSCs and activated MSCs∗ (44). Thus,
the comparison between cells studied in basal and in activated
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states shows that whereas the amounts of very significant
common GO terms and MSC GO terms are in concordance,
the results produced a significant variability and number of
pathways modified in MSCs∗ (44), and it demonstrates the
intense metabolic change that these activated cell exosomes have
suffered and the consequences after activation with radiation.
Among the cluster representatives in MSCs∗, we underline
the leukocyte cell–cell adhesion, cell localization, and negative
control of responses to activation and cell death. Several of
these proteins are important elements of cell–cell or cell–matrix
adhesion and include annexin and integrins. Among them, the
presence of ANXA1 is very significant because it is always present
in the exosomes secreted from MSCs∗ and constantly absent
in MSCs.
We have verified these findings using quantitative mRNA-
PCR to measure the mRNA of this molecule in MSCs andMSCs∗
and demonstrated that mRNA is dramatically induced in MSCs
after irradiation, which supports the massive presence of ANXA1
in the exosomes released byMSCs∗ (44). Especially relevant is the
presence of ANXA 1 in the exosomes from activated MSCs∗ and
the absence of this protein in the conditioned medium separated
from the non-irradiated MSCs.
During more than 30 years of research, annexins have been
established as key elements in the control immune responses.
The prototype member of this family, ANXA1, has been broadly
accepted as an anti-inflammatory intermediary influencing
migration and cellular reactions of various specialized cell types
of the innate immune system (129). Nevertheless, it is now
accepted that ANXA1 has extensive effects beyond the immune
system with consequences in preserving homeostatic secretion,
fetal development, the aging process, and development of several
diseases such as cancer (130, 131).
Inflammation is a strongly controlled process, initiated after
tissue damage or infection. If uncontrolled or unresolved, the
inflammation itself can drive additional tissue destruction and
cause persistent inflammatory disorders and autoimmunity with
following deficiency of organ function. It is now clear that the
control of inflammation is a functional process that appears
during an acute inflammatory incident (132). Following cell
activation and release, ANXA1 inhibits the accumulation of
neutrophils in the tissue injured by numerous mechanisms;
furthermore, ANXA1 promotes neutrophil apoptosis and takes
actions on macrophages to stimulate the phagocytosis and the
elimination of dead neutrophils (132, 133) and leads to the
rapid restoration of tissue homeostasis. Inflammation outcome is
regulated by numerous endogenous factors, involving fatty-acid-
derived specialized pre-resolving mediators and protein, such as
ANXA1 (134).
There is mounting evidence that ANXA1, and its mimetic
peptides (135), may have a major function in mitigating
ischemia–reperfusion injury-associated complications (136).
Moreover, chronic inflammation in tumors is frequent and
promotes tumor growth, progression, and metastatic spreading,
as well as treatment resistance (137). Physical aberrancies
of tumor vasculature comprise their chaotic organization, an
enhanced interstitial pressure, an amplified solid stress, hypoxia,
and a progressive contraction of solid tumors that are the
physical barriers in tumors (138) and are inspiring new anti-
cancer strategies aimed at targeting and normalizing the physical
anomalies of these solid tumors (139).
On the other hand, the overexpression of this molecule has
been reported in many cancers, although its clinical meaning
is still controversial (140–142), which could be, in part, due
to the localization of ANXA1 in the nuclear and cytoplasmic
compartments, and also associated to the membrane (131).
In fact, the expression level of ANXA1 is down-regulated in
numerous types of cancer and is linked with metastasis, relapse,
and poor prognosis (141, 143); ANXA1 is an endogenous
inhibitor of NF-κB that may be stimulated in human cancer cells
and in experimental mice models by powerful anti-inflammatory
glucocorticoids and altered by non-steroidal anti-inflammatory
drugs (143). In this context, ANXA1 has long been categorized
as an anti-inflammatory molecule due to its influence over
leukocyte-mediated immune responses (144).
Upon tissue damage, epithelial wound closure is a finely
adjusted process detected in chronic inflammatory diseases
related with non-healing wounds. In this process, ANXA1
is involved as a pre-resolving mediator (145). ANXA1 is a
glucocorticoid-induced protein that is well-known to reproduce
numerous anti-inflammatory effects of glucocorticoids and is
implicated in the modulation of T-cell function and the adaptive
immune response related to rheumatoid arthritis (146) and
increasing data suggest that ANXA1, which act together with
the formyl peptide receptor family, might have a major role in
alleviating ischemia–reperfusion injury (136). ANXA1 interacts
with p53 to co-regulate Bid expression and stimulate cell death
after OGD/R via the caspase-3 pathway (147) and it has been
described that ANXA1 is one of the molecules that is involved
in p53-mediated radio-response and the abnormal expression
of ANXA1 in nasopharyngeal carcinoma NPC might affect the
apoptosis of tumor cells caused by ionizing radiation decreasing
radiotherapeutic efficacy (148).
Recently, the function of ANXA1 in the therapy of acute
radiation-induced lung injury has been analyzed and the
mechanism of its action is investigated (149). The role of
damage-associated molecular patterns in neuro-inflammation
has been implicated in adverse neurological outcomes following
lethal hemorrhagic shock and polytrauma. Data obtained in
(150) provide new suggestion that appealing pro-resolving
pharmacological approaches such as Annexin-A1 biomimetic
peptides can effectively reduce neuro-inflammation and new
data show a new multifaceted role for ANXA1 as a therapeutic
and a prophylactic drug due to its capacity to stimulate
endogenous pro-resolving, anti-thrombo-inflammatory circuits
in cerebral ischemia–reperfusion injury (151). Finally, the chance
of exploiting ANXA1 as a novel therapeutic molecule in
diabetes and for treatment of microvascular disease has been
announced (152).
CONCLUSIONS
Considering all the information summarized in this review,
we are convinced that, due to (i) the physical hallmarks and
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biological capabilities (153) that characterize neoplastic tissues,
(ii) the physical–chemical tropism of MSCs (154), and (iii)
the widespread functions of macromolecules, proteins, and
exosomes, all these factors secreted by activated MSCs∗ are able
to reduce pro-tumorigenic and pro-metastatic signals released by
tumors that influence the progression, growth, spread, and drug
resistance of tumor cells.
However, additional study is required to find the cause of
tumor cells forsaking malign phenotypes of cancer cells and
returning to their normal state.
We have recently shown that clinical grade umbilical cord
MSCs can be expanded, cryogenically stored, and reconstituted
after batch release, maintaining their immunophenotype,
and show good viability and activation by irradiation.
Our study indicates that no toxic effects are produced by
MSCs or pre-irradiated MSC∗ inoculation. In addition,
umbilical cord MSCs∗ have never been detected in any
studied organ at 90 days, indicating that these cells will not
be present for a long time in a treated patient (manuscript
in preparation).
In an attempt to take our basic and regulatory research to
clinical practice, we proceeded to apply for the registration of
the patent P201500022 and title “Activated stem cells and medical
uses,” with the priority date of December 2014. Its international
extension via PCT has the number PCT/ES2015/070951
(WO/2016/102735) and was published in June 2016.
Therefore, we conclude that umbilical cord mesenchymal cells
combined with radiotherapy are adequate for therapeutic use in a
clinical trial in patients with cancer due to the fact that increasing
the therapeutic effect of radiotherapy on the tumors and possible
metastatic foci improves the radiotherapy outcome.
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